NCT03020095 - Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

February 28, 2017

Conditions

Chronic Hepatitis C

Interventions

DRUG

Ravidasvir

Ravidasvir 200mg tablet administered orally once daily

DRUG

Danoprevir

Danoprevir 100mg tablet administered orally twice daily

DRUG

Ritonavir

Ritonavir 100mg tablet administered orally twice daily

DRUG

Ribavirin

Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally